Market research
R5WP.F Trillium Therapeutics Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 570M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.98
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 570M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.98
About
About Trillium Therapeutics Inc
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the R5WP.F discussion.
5 years, 5 months ago
Trillium Therapeutics Inc is currently in a long term downtrend where the price is trading 26.7% below its 200 day moving average.
From a valuation standpoint, the stock is 383.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6350.5.
Trillium Therapeutics Inc's total revenue rose by 5246.8% to $33K since the same quarter in the previous year.
Its net income has increased by 694.1% to $114M since the same quarter in the previous year.
Finally, its free cash flow fell by 22.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Trillium Therapeutics Inc gets an overall score of 2/5.